Physician profile
Sandra Rae
NPI 1750423430
$1,280.82
in general payments reported to CMS, 2019-2025
12 companies · $549 in 2025
The $549 reported for 2025 was more than what 88% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.23 · 2022: $40.72 · 2023: $236 · 2024: $377 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $556.41 | 2023-2025 | Xeomin |
| Abbvie INC. | $304.89 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $84.66 | 2025 | |
| Painteq LLC | $70.84 | 2024 | Painteq |
| Allergan, INC. | $64.82 | 2021 | |
| Bioventus LLC | $49.76 | 2023-2025 | Xcell, Durolane |
| Lundbeck LLC | $45.06 | 2024-2025 | Vyepti |
| Vertos Medical, INC. | $28.12 | 2024 | Mild Device Kit |
| Medtronic, INC. | $23.09 | 2024 | Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $20.25 | 2025 | Evoke |
| Depuy Synthes Sales INC. | $18.51 | 2022 | |
| Emd Serono, INC. | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.